Hematology
News
FDA halts enrollment in trial of venetoclax for multiple myeloma
Increased risk of fatal infections
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patients
However, the reduction lost significance if treatment with rivaroxaban was halted.
Clinical Topics & News
Risk of Cancer-Associated Thrombosis and Bleeding in Veterans With Malignancy Who Are Receiving DOACs
The low incidence of venous thromboembolism formation in this study and similar rates of bleeding in other clinical trials indicate that direct...
News
Poor-prognosis cancers linked to highest suicide risk in first year
Pancreatic and lung cancer patients had high rates of suicide in comparison to the general population, while breast and prostate cancer patients...
Conference Coverage
ALL chemotherapy looks effective in mixed phenotype leukemia
SAN DIEGO – In a retrospective cohort study, most children with mixed phenotype acute leukemia achieved MRD-negative complete response on ALL-...
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
Conference Coverage
Factor IX expression stable at up to 8 years with gene therapy
SAN DIEGO – In severe hemophilia B, factor IX expression remains stable up to 8.6 years after scAAV2/8-LP1-hFIX–comediated gene therapy.
Conference Coverage
Lower-dose rituximab may be enough in acquired TTP
SAN DIEGO – A lower dose of rituximab appears effective, but it still carries side effects.
Video
Model bests IPSS-R for predicting survival, risk for AML in myelodysplastic syndrome
